Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia

Neuropsychopharmacology

Volumn 35, Issue 5, 2010, Pages 1155-1164

  Syu, Aoi ^a,b   Ishiguro, Hiroki ^a,b   Inada, Toshiya ^c   Horiuchi, Yasue ^a,b   Tanaka, Syunsuke ^a   Ishikawa, Maya ^a   Arai, Makoto ^d   Itokawa, Masanari ^d   Niizato, Kazuhiro ^e   Iritani, Shuji ^e   Ozaki, Norio ^f   Takahashi, Makoto ^g   Kakita, Akiyoshi ^h   Takahashi, Hitoshi ^h   Nawa, Hiroyuki ^h   Keino Masu, Kazuko ^a   Arikawa Hirasawa, Eri ⁱ   Arinami, Tadao ^a,b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c SEIWA HOSPITAL   (Japan)

^d TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^e TOKYO METROPOLITAN MATSUZAWA HOSPITAL   (Japan)

^f NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^h NIIGATA UNIVERSITY   (Japan)

ⁱ JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acetylcholine; Neurogenetics; Pharmacogenetics pharmacogenomics; Schizophrenia antipsychotics; Tardive dyskinesia

Indexed keywords

HALOPERIDOL; HEPARAN SULFATE PROTEOGLYCAN 2; PHYSOSTIGMINE; PROTEOHEPARAN SULFATE; RESERPINE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CADAVER; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; HUMAN; HUMAN TISSUE; JAPANESE; MAJOR CLINICAL STUDY; MALE; MOUSE; NEUROLEPTIC INDUCED TARDIVE DYSKINESIA; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA; VACUOUS CHEWING MOVEMENT; WILD TYPE;

ANIMALS; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; DYSKINESIA, DRUG-INDUCED; FEMALE; GENETIC ASSOCIATION STUDIES; HALOPERIDOL; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; JAPAN; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHYSOSTIGMINE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREFRONTAL CORTEX; RESERPINE; SCHIZOPHRENIA;

EID: 77949540851     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.220     Document Type: Article

References (35)

1. Araujo NP, Abilio VC, Silva RH, Pereira RC, Carvalho RC, Gonzalez C et al (2004). Effects of topiramate on oral dyskinesia induced by reserpine. Brain Res Bull 64: 331-337.
2. Arikawa-Hirasawa E, Watanabe H, Takami H, Hassell JR, Yamada Y (1999). Perlecan is essential for cartilage and cephalic development. Nat Genet 23: 354-358.
3. Association AP (1994). Diagnostic and Statistical Manual of Mental Disorders. 4th Revision. American Psychiatric Association: Washington DC.
4. Ben-Shachar D, Livne E, Spanier I, Zuk R, Youdim MB (1993). Iron modulates neuroleptic-induced effects related to the dopami-nergic system. Isr J Med Sci 29: 587-592.
5. Burger ME, Fachineto R, Alves A, Callegari L, Rocha JB (2005). Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats. Brain Res 1031: 202-210.
6. Caroff SN, Campbell EC, Havey J, Sullivan KA, Mann SC, Gallop R (2001). Treatment of tardive dyskinesia with donepezil: a pilot study. J Clin Psychiatry 62: 772-775.
7. de Leon J (2007). The effect of atypical versus typical antipsycho-tics on tardive dyskinesia: A Naturalistic Study. Eur Arch Psychiatry Clin Neurosci 257: 169-172.
8. Deguchi Y, Okutsu H, Okura T, Yamada S, Kimura R, Yuge T et al (2002). Internalization of basic fibroblast growth factor at the mouse blood-brain barrier involves perlecan, a heparan sulfate proteoglycan. J Neurochem 83: 381-389.
9. Devlin B, Roeder K (1999). Genomic control for association studies. Biometrics 55: 997-1004.
10. Devlin B, Roeder K, Wasserman L (2001). Genomic control, a new approach to genetic-based association studies. Theor Popul Biol 60: 155-166.
11. Feng G, Krejci E, Molgo J, Cunningham JM, Massoulie J, Sanes JR (1999). Genetic analysis of collagen Q: roles in acetylcholinester-ase and butyrylcholinesterase assembly and in synaptic structure and function. J Cell Biol 144: 1349-1360.
12. Gerlach J (2002). Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry 14: 47-57.
13. Gerlach J, Casey DE (1988). Tardive dyskinesia. Acta Psychiatr Scand 77: 369-378.
14. Haleem DJ (2006). Serotonergic modulation of dopamine neuro-transmission: a mechanism for enhancing therapeutics in schizophrenia. J Coll Physicians Surg Pak 16: 556-562.
15. Inada T, Koga M, Ishiguro H, Horiuchi Y, Syu A, Yoshio T et al (2008). Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics 18: 317-323.
16. Ishiguro H, Koga M, Horiuchi Y, Noguchi E, Morikawa M, Suzuki Y et al (2008). Supportive evidence for reduced expression of GNB1L in schizophrenia. Schizophr Bull. Print copy in press (originally published online 14 November, 2008, at schizophreniabulletin.oxfordjournals.org/cgi/reprint/sbn160v1).
17. Klawans HL, Goetz CG, Perlik S (1980). Tardive dyskinesia: review and update. Am J Psychiatry 137: 900-908.
18. Koga M, Ishiguro H, Yazaki S, Horiuchi Y, Arai M, Niizato K et al (2009). Involvement of SMARCA2/BRM in the SWI/SNF chromatin-remodeling complex in schizophrenia. Hum Mol Genet 18: 2483-2494.
19. Leadbeater WE, Gonzalez AM, Logaras N, Berry M, Turnbull JE, Logan A (2006). Intracellular trafficking in neurones and glia of fibroblast growth factor-2, fibroblast growth factor receptor 1 and heparan sulphate proteoglycans in the injured adult rat cerebral cortex. J Neurochem 96: 1189-1200.
20. Malhotra AK, Murphy Jr GM., Kennedy JL (2004). Pharmacoge-netics of psychotropic drug response. Am J Psychiatry 161: 780-796.
21. Menza MA, Grossman N, Van Horn M, Cody R, Forman N (1991). Smoking and movement disorders in psychiatric patients. Biol Psychiatry 30: 109-115.
22. Muller DJ, Shinkai T, De Luca V, Kennedy JL (2004). Clinical implications of pharmacogenomics for tardive dyskinesia. Pharmacogenomics J 4: 77-87.
23. Naidu PS, Singh A, Kaur P, Sandhir R, Kulkarni SK (2003). Possible mechanism of action in melatonin attenuation of haloperidol-induced orofacial dyskinesia. Pharmacol Biochem Behav 74: 641-648.
24. Peng HB, Xie H, Rossi SG, Rotundo RL (1999). Acetylcholinester-ase clustering at the neuromuscular junction involves perlecan and dystroglycan. J Cell Biol 145: 911-921.
25. Perrier AL, Massoulie J, Krejci E (2002). PRiMA: the membrane anchor of acetylcholinesterase in the brain. Neuron 33: 275-285.
26. Remington G (2007). Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiatry 20: 131-137.
27. Riva MA, Molteni R, Tascedda F, Massironi A, Racagni G (1999). Selective modulation of fibroblast growth factor-2 expression in the rat brain by the atypical antipsychotic clozapine. Neuro-pharmacology 38: 1075-1082.
28. Rotundo RL, Rossi SG, Kimbell LM, Ruiz C, Marrero E (2005). Targeting acetylcholinesterase to the neuromuscular synapse. Chem Biol Interact 157-158: 15-21.
29. Sachdev PS (2000). The current status of tardive dyskinesia. Aust N Z J Psychiatry 34: 355-369.
30. Saito T, Ishizawa H, Tsuchiya F, Ozawa H, Takahata N (1986). Neurochemical findings in the cerebrospinal fluid of schizophrenic patients with tardive dyskinesia and neuroleptic-induced parkinsonism. Jpn J Psychiatry Neurol 40: 189-194.
31. Schooler NR, Kane JM (1982). Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39: 486-487.
32. Tammenmaa IA, McGrath JJ, Sailas E, Soares-Weiser K (2002). Cholinergic medication for neuroleptic-induced tardive dyski-nesia. Cochrane Database Syst Rev 3: CD000207.
33. Tammenmaa IA, Sailas E, McGrath JJ, Soares-Weiser K, Wahlbeck K (2004). Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry 28: 1099-1107.
34. Tarsy D, Baldessarini RJ (2006). Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 21: 589-598.
35. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA (1996). The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 271: 10079-10086.